Last reviewed · How we verify

Ciclosporin and Mycophenolate-mofetil — Competitive Intelligence Brief

Ciclosporin and Mycophenolate-mofetil (Ciclosporin and Mycophenolate-mofetil) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressant combination. Area: Immunology.

marketed Immunosuppressant combination Calcineurin (ciclosporin); IMPDH type II (mycophenolate mofetil) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Ciclosporin and Mycophenolate-mofetil (Ciclosporin and Mycophenolate-mofetil) — University of Giessen. This combination suppresses T-cell activation and proliferation through calcineurin inhibition (ciclosporin) and inosine monophosphate dehydrogenase inhibition (mycophenolate mofetil) to prevent organ rejection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ciclosporin and Mycophenolate-mofetil TARGET Ciclosporin and Mycophenolate-mofetil University of Giessen marketed Immunosuppressant combination Calcineurin (ciclosporin); IMPDH type II (mycophenolate mofetil)
Mycophenolate to sirolimus switch Mycophenolate to sirolimus switch London Health Sciences Centre marketed Immunosuppressant combination therapy mTOR (sirolimus component); IMPDH (mycophenolate component being replaced)
Tacrolimus and Mycophenolate-mofetil Tacrolimus and Mycophenolate-mofetil University of Giessen marketed Immunosuppressant combination (calcineurin inhibitor + antimetabolite) Calcineurin (tacrolimus); IMPDH type II (mycophenolate mofetil)
Tacrolimus/MMF Tacrolimus/MMF University of Miami marketed Immunosuppressant combination Calcineurin (tacrolimus); IMPDH type II (MMF)
XR-tacrolimus QD + MMF BID XR-tacrolimus QD + MMF BID University Hospital, Limoges marketed Calcineurin inhibitor + Antimetabolite immunosuppressant combination Calcineurin (tacrolimus); IMPDH type II (mycophenolate mofetil)
LCP-tacrolimus QD + MMF QD then MMF QD LCP-tacrolimus QD + MMF QD then MMF QD University Hospital, Limoges marketed Calcineurin inhibitor + antimetabolite immunosuppressant combination Calcineurin (tacrolimus); inosine monophosphate dehydrogenase type II (MMF)
MMF (Cellcept) and Steroids MMF (Cellcept) and Steroids University of Luebeck marketed Immunosuppressant combination (inosine monophosphate dehydrogenase inhibitor + corticosteroid) IMPDH type II; glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressant combination class)

  1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 drug in this class
  2. St. Anne's University Hospital Brno, Czech Republic · 1 drug in this class
  3. Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · 1 drug in this class
  4. University of Giessen · 1 drug in this class
  5. University of Miami · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ciclosporin and Mycophenolate-mofetil — Competitive Intelligence Brief. https://druglandscape.com/ci/ciclosporin-and-mycophenolate-mofetil. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: